Deletion of IL-4Rα on CD4 T cells renders BALB/c mice resistant to Leishmania major infection

PLoS Pathogens

Volumn 3, Issue 5, 2007, Pages 0619-0629

  Radwanska, Magdalena ^a   Cutler, Antony J ^a   Hoving, J Claire ^a   Magez, Stefan ^a,b   Holscher, Christoph ^a   Bohms, Andreas ^a   Arendse, Berenice ^a   Kirsch, Richard ^a   Hunig, Thomas ^c   Alexander, James ^d   Kaye, Paul ^e   Brombacher, Frank ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^e UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; MESSENGER RNA; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; INTERLEUKIN 12; NITRIC OXIDE; NOS2 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; GENE DELETION; GENE EXPRESSION; GENE INDUCTION; INFECTION RESISTANCE; LEISHMANIA MAJOR; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PHENOTYPE; PROTECTION; SIGNAL TRANSDUCTION; SKIN LEISHMANIASIS; SKIN ULCER; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; WOUND HEALING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PARASITOLOGY; PATHOGENICITY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETION;

LEISHMANIA MAJOR; MUS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TH1 CELLS; TH2 CELLS;

EID: 34249658382     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.0030068     Document Type: Article

References (63)

1. Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
2. Locksley RM, Scott P (1991) Helper T-cell subsets in mouse leishmaniasis: Induction, expansion and effector function. Immunol Today 12: A58-A61.
3. Reiner SL, Locksley RM (1995) The regulation of immunity to Leishmania major. Annu Rev Immunol 13: 151-177.
4. Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, et al. (2000) IL-13 is a susceptibility factor for Leishmania major infection. J Immunol 164: 1458-1462.
5. Arendse B, Van Snick J, Brombacher F (2005) IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses. J Immunol 174: 2205-2211.
6. Kopf M, Brombacher F, Kohler G, Kienzle G, Widmann KH, et al. (1996) IL-4-deficient Balb/c mice resist infection with Leishmania major. J Exp Med 184: 1127-1136.
7. Mohrs M, Holscher C, Brombacher F (2000) Interleukin-4 receptor alpha-deficient BALB/c mice show an unimpaired T helper 2 polarization in response to Leishmania major infection. Infect Immun 68: 1773-1780.
8. Iniesta V, Gomez-Nieto LC, Molano I, Mohedano A, Carcelen J, et al. (2002) Arginase I induction in macrophages, triggered by Th2-type cytokines, supports the growth of intracellular Leishmania parasites. Parasite Immunol 24: 113-118.
9. Holscher C, Arendse B, Schwegmann A, Myburgh E, Brombacher F (2006) Impairment of alternative macrophage activation delays cutaneous leishmaniasis in nonhealing BALB/c mice. J Immunol 176: 1115-1121.
10. Laskay T, Diefenbach A, Rollinghoff M, Solbach W (1995) Early parasite containment is decisive for resistance to Leishmania major infection. Eur J Immunol 25: 2220-2227.
11. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK (1993) Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 177: 1505-1509.
12. Sypek JP, Chung CL, Mayor SE, Subramanyam JM, Goldman SJ, et al. (1993) Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 177: 1797-1802.
13. Park AY, Hondowicz B, Kopf M, Scott P (2002) The role of IL-12 in maintaining resistance to Leishmania major. J Immunol 168: 5771-5777.
14. Guler ML, Gorham JD, Hsieh CS, Mackey AJ, Steen RG, et al. (1996) Genetic susceptibility to Leishmania: IL-12 responsiveness in TH1 cell development. Science 271: 984-987.
15. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A (1988) Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 168: 1675-1684.
16. + cells correlate with resolution of lesions in murine cutaneous leishmaniasis. J Immunol 149: 2715-2721.
17. Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, et al. (2000) A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 165: 969-977.
18. + T cells during initiation of infection. J Exp Med 179: 447-456.
19. Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, et al. (1990) Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J Exp Med 171: 115-127.
20. Mohrs M, Ledermann B, Kohler G, Dorfmuller A, Gessner A, et al. (1999) Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J Immunol 162: 7302-7308.
21. Noben-Trauth N, Kropf P, Muller I (1996) Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 271: 987-990.
22. McKenzie GJ, Emson CL, Bell SE, Anderson S, Fallon P, et al. (1998) Impaired development of Th2 cells in IL-13-deficient mice. Immunity 9: 423-432.
23. Zurawski G, de Vries JE (1994) Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15: 19-26.
24. Herbert DR, Holscher C, Mohrs M, Arendse B, Schwegmann A, et al. (2004) Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 20: 623-635.
25. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD (2003) Interleukin-4 and interleukin-13 signaling connections maps. Science 300: 1527-1528.
26. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE (1999) The IL-4 receptor: Signaling mechanisms and biologic functions. Annu Rev Immunol 17: 701-738.
27. Swain SL, Weinberg AD, English M, Huston G (1990) IL-4 directs the development of Th2-like helper effectors. J Immunol 145: 3796-3806.
28. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K (1994) Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science 265: 103-106.
29. + T cells. Annu Rev Immunol 12: 635-673.
30. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, et al. (1996) Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380: 630-633.
31. Noben-Trauth N, Lira R, Nagase H, Paul WE, Sacks DL (2003) The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J Immunol 170: 5152-5158.
32. Heinzel FP, Rerko RM (1999) Cure of progressive murine leishmaniasis: Interleukin 4 dominance is abolished by transient CD4(+) T cell depletion and T helper cell type 1-selective cytokine therapy. J Exp Med 189: 1895-1906.
33. Gazzinelli RT, Oswald IP, James SL, Sher A (1992) IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. J Immunol 148: 1792-1796.
34. Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, et al. (1996) Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 26: 1553-1559.
35. Stenger S, Thuring H, Rollinghoff M, Bogdan C (1994) Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major. J Exp Med 180: 783-793.
36. Rajewsky K, Gu H, Kuhn R, Betz UA, Muller W, et al. (1996) Conditional gene targeting. J Clin Invest 98: 600-603.
37. Bogdan C, Vodovotz Y, Nathan C (1991) Macrophage deactivation by interleukin 10. J Exp Med 174: 1549-1555.
38. Vieth M, Will A, Schroppel K, Rollinghoff M, Gessner A (1994) Interleukin-10 inhibits antimicrobial activity against Leishmania major in murine macrophages. Scand J Immunol 40: 403-409.
39. Kane MM, Mosser DM (2001) The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 166: 1141-1147.
40. Li L, Elliott JF, Mosmann TR (1994) IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. J Immunol 153: 3967-3978.
41. + lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc Natl Acad Sci U S A 88: 7011-7015.
42. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, et al. (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 1497-1506.
43. Miles SA, Conrad SM, Alves RG, Jeronimo SM, Mosser DM (2005) A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 201: 747-754.
44. + natural regulatory T cells are specific for microbial antigens. J Exp Med 203: 777-788.
45. + regulatory T cells control Leishmania major persistence and immunity. Nature 420: 502-507.
46. - Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 204: 285-297.
47. + T cells. J Immunol 169: 3232-3241.
48. + regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J Immunol 170: 394-399.
49. + T cell suppressor function. Eur J Immunol 34: 366-376.
50. + regulatory T cell-mediated suppression. J Immunol 176: 3900-3904.
51. Cher DJ, Mosmann TR (1987) Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J Immunol 138: 3688-3694.
52. Barner M, Mohrs M, Brombacher F, Kopf M (1998) Differences between IL-4R alpha-deficient and IL-4-deficient mice reveal a role for IL-13 in the regulation of Th2 responses. Curr Biol 8: 669-672.
53. + lymphocytes with a Th2 cytokine profile. J Immunol 164: 3047-3055.
54. Brewer JM, Conacher M, Hunter CA, Mohrs M, Brombacher F, et al. (1999) Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 163: 6448-6454.
55. Biedermann T, Zimmermann S, Himmelrich H, Gumy A, Egeter O, et al. (2001) IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2: 1054-1060.
56. + T helper type 1 cell responses to Candida albicans. J Exp Med 187: 307-317.
57. Minty A, Ferrara P, Caput D (1997) Interleukin-13 effects on activated monocytes lead to novel cytokine secretion profiles intermediate between those induced by interleukin-10 and by interferon-gamma. Eur Cytokine Netw 8: 189-201.
58. Flesch IE, Wandersee A, Kaufmann SH (1997) Effects of IL-13 on murine listeriosis. Int Immunol 9: 467-474.
59. Iezzi G, Frohlich A, Ernst B, Ampenberger F, Saeland S, et al. (2006) Lymph node resident rather than skin-derived dendritic cells initiate specific T cell responses after Leishmania major infection. J Immunol 177: 1250-1256.
60. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F (2000) Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol 30: 2935-2943.
61. + T-cell responses. Nat Med 9: 1287-1292.
62. - T cell activation in the presence of T regulatory cells. J Immunol 175: 641-645.
63. Nicolas L, Prina E, Lang T, Milon G (2002) Real-time PCR for detection and quantitation of leishmania in mouse tissues. J Clin Microbiol 40: 1666-1669.